Kymera Therapeutics, Inc. $KYMR Stock Holdings Increased by Odyssean LLC

Odyssean LLC boosted its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 132.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,485 shares of the company’s stock after buying an additional 19,664 shares during the quarter. Kymera Therapeutics accounts for approximately 0.6% of Odyssean LLC’s portfolio, making the stock its 2nd largest holding. Odyssean LLC’s holdings in Kymera Therapeutics were worth $3,954,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its stake in shares of Kymera Therapeutics by 27.5% during the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after acquiring an additional 98 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after acquiring an additional 424 shares during the period. Larson Financial Group LLC increased its stake in Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Kymera Therapeutics in the 4th quarter valued at approximately $63,000. Finally, Osaic Holdings Inc. raised its holdings in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the last quarter.

Kymera Therapeutics Stock Performance

KYMR stock opened at $126.64 on Wednesday. Kymera Therapeutics, Inc. has a 1 year low of $39.84 and a 1 year high of $130.05. The stock’s 50 day moving average price is $110.92 and its 200 day moving average price is $92.80. The firm has a market cap of $10.53 billion, a P/E ratio of -39.09 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The firm had revenue of $65.00 million for the quarter, compared to analysts’ expectations of $32.78 million. During the same quarter in the prior year, the firm earned ($0.95) EPS. Kymera Therapeutics’s quarterly revenue was up 465.2% on a year-over-year basis. On average, research analysts predict that Kymera Therapeutics, Inc. will post -3.75 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on KYMR shares. B. Riley Financial boosted their target price on Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Canaccord Genuity Group raised their price target on Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a research report on Friday, June 26th. Loop Capital set a $97.00 price target on Kymera Therapeutics in a research note on Monday, June 8th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Kymera Therapeutics in a research report on Thursday, July 30th. They issued a “hold” rating and a $120.00 price objective on the stock. Finally, Citigroup reissued a “buy” rating on shares of Kymera Therapeutics in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Kymera Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $125.65.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Bruce Booth sold 31,283 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $109.48, for a total transaction of $3,424,862.84. Following the sale, the director owned 461,794 shares of the company’s stock, valued at $50,557,207.12. This trade represents a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Noah Goodman sold 3,389 shares of Kymera Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $114.29, for a total value of $387,328.81. Following the sale, the insider owned 47,179 shares of the company’s stock, valued at approximately $5,392,087.91. This represents a 6.70% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 3,587,629 shares of company stock valued at $386,183,782. 15.98% of the stock is owned by company insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.